Table 4.

95% confidence intervals (CI) for differences of main comparisons of effects of 5 and 10 mg doses of asimadoline vs placebo and of 5 vs 10 mg doses of asimadoline in the absence or presence of 2.5% saline infusion i.v.(V = urinary flow rate; C_H2O = free-water clearance); *P < 0.05, **P < 0.01.

Parameters		Collection interval 5 mg asimadoline vs placebo mean of difference ± s.d.	95% CI	10 mg asimadoline vs placebo mean of difference ± s.d	95% CI	10 mg vs 5 mg asimadoline Mean of difference.	95% CI
V (ml min−1)	0–2 h	2.34 ± 1.91	0.74,3.93 **	2.26 ± 1.40	1.09–3.44 **	−0.13	−2.24,1.99
	2–4 h (2.5% NaCl)	0.21 ± 0.71	−0.38,0.81	0.86 ± 1.01	0.02–1.71 **	0.99	−0.32,2.30
CH2O (ml min−1)
	0–2 h	2.58 ± 2.11	0.37,4.79 *	2.60 ± 1.18	1.51–3.69	0.53	−1.22,2.28
	2–4 h (2.5% NaCl)	−0.04 ± 0.74	−0.66,0.58	0.85 ± 0.61	0.34,1.36	0.80	−0.16,1.76
Plasma AVP concentration
(fmol ml−1)	0–2 h	−0.68 ± 1.82	−2.20,0.84	0.58 ± 2.66	−1.65,2.81	1.57	−0.57,3.71
	2–4 h (2.5% NaCl)	−0.15 ± 3.02	−2.69,2.38	−1.54 ± 3.36	−4.35,1.27 *	0.07	−2.32,2.46
Urinary AVP excretion
(fmol min−1)	0–2 h	−0.88 ± 10.42	−9.60,7.84	−20.59 ± 11.94	−30.58,-10.60*	3.86	10.74,18.46
	2–4 h (2.5% NaCl)	23.57 ± 100.71	−60.63,107.8	229.82 ± 256.42	−444.2,-15.45	−63.12*	−178.49.52.25
Urinary cAMP excretion
(pmol min−1)	0–2 h	0.11 ± 0.89	−0.64,0.86	−0.25 ± 0.13	−0.36,-0.14	−0.28	−0.95,0.40
	2–4 h (2.5% NaCl)	−0.14 ± 1.12	−1.07,0.80	0.00 ± 0.83	−0.77,0.77	−0.28	−1.26,0.71
Plasma ANP concentration
(pmol l−1)	0–2 h	−1.62 ± 3.13	−4.23,1.00	−1.37 ± 3.43	−4.23,1.50	−1.01	−3.24,1.22
	2–4 h (2.5% NaCl)	0.65 ± 1.42	−0.54,1.84	0.39 ± 3.34	−2.41,3.18	0.52	−3.34,4.47
Plasma ET-1 concentration
(pmol l−1)	0–2 h	−0.64 ± 2.26	−2.53,1.25	−0.16 ± 1.28	−1.13,2.51	−0.42	−1.78,0.94
	2–4 h (2.5% NaCl)	−1.85 ± 3.16	−1.80,0.32	0.59 ± 1.24	−0.45,1.62	−0.04	−1.34,1.27
Urinary ET-1 excretion
(pmol min−1)	0–2 h	5.65 ± 13.83	−5.90,10.31	−5.29 ± 11.88	−15.21,4.65	−11.48	−25.39,2.42
	2–4 h (2.5% NaCl)	−0.12 ± 12.19	−10.31,10.08	2.17 ± 9.18	−5.51,9.84	3.89	−11.44,19.20